These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. Corey L; Langenberg AG; Ashley R; Sekulovich RE; Izu AE; Douglas JM; Handsfield HH; Warren T; Marr L; Tyring S; DiCarlo R; Adimora AA; Leone P; Dekker CL; Burke RL; Leong WP; Straus SE JAMA; 1999 Jul; 282(4):331-40. PubMed ID: 10432030 [TBL] [Abstract][Full Text] [Related]
12. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. Mertz GJ; Ashley R; Burke RL; Benedetti J; Critchlow C; Jones CC; Corey L J Infect Dis; 1990 Apr; 161(4):653-60. PubMed ID: 2181031 [TBL] [Abstract][Full Text] [Related]
13. Detection of type-specific antibody to herpes simplex virus type 1 by radioimmunoassay with herpes simplex virus type 1 glycoprotein C purified with monoclonal antibody. Arvin AM; Koropchak CM; Yeager AS; Pereira L Infect Immun; 1983 Apr; 40(1):184-9. PubMed ID: 6832831 [TBL] [Abstract][Full Text] [Related]
14. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]. Langenberg AG; Burke RL; Adair SF; Sekulovich R; Tigges M; Dekker CL; Corey L Ann Intern Med; 1995 Jun; 122(12):889-98. PubMed ID: 7755223 [TBL] [Abstract][Full Text] [Related]
15. Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): comparative protection against lethal challenge in mice. Ghiasi H; Kaiwar R; Nesburn AB; Slanina S; Wechsler SL J Virol; 1994 Apr; 68(4):2118-26. PubMed ID: 8138996 [TBL] [Abstract][Full Text] [Related]
16. The immune response to herpes simplex virus: comparison of the specificity and relative titers of serum antibodies directed against viral polypeptides following primary herpes simplex virus type 1 infections. Eberle R; Mou SW; Zaia JA J Med Virol; 1985 Jun; 16(2):147-62. PubMed ID: 2409225 [TBL] [Abstract][Full Text] [Related]
17. Cervical antibody responses to a herpes simplex virus type 2 glycoprotein subunit vaccine. Ashley RL; Crisostomo FM; Doss M; Sekulovich RE; Burke RL; Shaughnessy M; Corey L; Polissar NL; Langenberg AG J Infect Dis; 1998 Jul; 178(1):1-7. PubMed ID: 9652416 [TBL] [Abstract][Full Text] [Related]
18. Immune response to a DNA free herpes simplex vaccine in man. Cappel R; Sprecher S; Rickaert F; de Cuyper F Arch Virol; 1982; 73(1):61-7. PubMed ID: 6289778 [TBL] [Abstract][Full Text] [Related]
19. Patient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus Are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific. Cairns TM; Huang ZY; Gallagher JR; Lin Y; Lou H; Whitbeck JC; Wald A; Cohen GH; Eisenberg RJ J Virol; 2015 Sep; 89(18):9213-31. PubMed ID: 26109729 [TBL] [Abstract][Full Text] [Related]